All patients
Age < 65y (younger) Age > 65y ECOG 0 ECOG 1 Gender, female Gender, male LDH > ULN LDH ≤ULN PD-L1 < 1% PD-L1 > 1% stage IIIc stage IV (metastatic) stage M0 stage M1A stage M1B stage M1C
Top evidence (RCT only, high risk of bias excluded)
Best available evidence (possibly low or very low)
All RCTs
All studies (RCT+OBS)
mML - L1 - BRAF mutant, immune chekpoint inhibitors vs. all, meta-analysis of study results Outcome TE 95% CI n k I2 ROB Pub. bias deaths (OS)detailed results CheckMate 069 (BRAF mutant) EXPLORATORY, 2015 1.44 [0.46; 4.49]
IMspire-150 (BRAF mutant), 2020 0.85 [0.65; 1.12]
0.88 [0.67 ; 1.14 ] CheckMate 069 (BRAF mutant) EXPLORATORY, 2015, IMspire-150 (BRAF mutant), 2020 2 0% 547 low not evaluable PFS (extension)detailed results CheckMate 069 (BRAF mutant) EXPLORATORY, 2015 0.47 [0.10; 2.27]
0.47 [0.10 ; 2.27 ] CheckMate 069 (BRAF mutant) EXPLORATORY, 2015 1 0% 33 NA not evaluable progression or deaths (PFS)detailed results CheckMate 069 (BRAF mutant) EXPLORATORY, 2015 0.38 [0.15; 0.98]
IMspire-150 (BRAF mutant), 2020 0.78 [0.63; 0.97]
0.64 [0.34 ; 1.20 ] CheckMate 069 (BRAF mutant) EXPLORATORY, 2015, IMspire-150 (BRAF mutant), 2020 2 52% 547 low not evaluable objective responses (ORR)detailed results CheckMate 069 (BRAF mutant) EXPLORATORY, 2015 9.82 [0.45; 212.91]
IMspire-150 (BRAF mutant), 2020 1.19 [0.83; 1.71]
1.92 [0.34 ; 10.88 ] CheckMate 069 (BRAF mutant) EXPLORATORY, 2015, IMspire-150 (BRAF mutant), 2020 2 44% 547 low not evaluable objective responses (ORR) (extension)detailed results CheckMate 069 (BRAF mutant) EXPLORATORY, 2015 9.80 [0.45; 211.42]
9.80 [0.45 ; 211.42 ] CheckMate 069 (BRAF mutant) EXPLORATORY, 2015 1 0% 33 NA not evaluable AE leading to death (grade 5)detailed results IMspire-150 (BRAF mutant), 2020 1.23 [0.42; 3.56]
1.23 [0.42 ; 3.56 ] IMspire-150 (BRAF mutant), 2020 1 0% 511 NA not evaluable AE leading to treatment discontinuation (any grade)detailed results IMspire-150 (BRAF mutant), 2020 0.78 [0.47; 1.29]
0.78 [0.47 ; 1.29 ] IMspire-150 (BRAF mutant), 2020 1 0% 511 NA not evaluable STRAE (any grade)detailed results IMspire-150 (BRAF mutant), 2020 1.24 [0.85; 1.81]
1.24 [0.85 ; 1.81 ] IMspire-150 (BRAF mutant), 2020 1 0% 511 NA not evaluable TRAE (any grade)detailed results IMspire-150 (BRAF mutant), 2020 0.82 [0.11; 5.85]
0.82 [0.11 ; 5.85 ] IMspire-150 (BRAF mutant), 2020 1 0% 511 NA not evaluable TRAE (grade 3-4)detailed results IMspire-150 (BRAF mutant), 2020 1.41 [0.93; 2.12]
1.41 [0.93 ; 2.12 ] IMspire-150 (BRAF mutant), 2020 1 0% 511 NA not evaluable Arthralgia TRAE (grade 3-4)detailed results IMspire-150 (BRAF mutant), 2020 1.44 [0.48; 4.34]
1.44 [0.48 ; 4.34 ] IMspire-150 (BRAF mutant), 2020 1 0% 511 NA not evaluable Asthenia TRAE (grade 3-4)detailed results IMspire-150 (BRAF mutant), 2020 2.47 [0.45; 13.60]
2.47 [0.45 ; 13.60 ] IMspire-150 (BRAF mutant), 2020 1 0% 511 NA not evaluable Blood creatinine increased TRAE (grade 3-4)detailed results IMspire-150 (BRAF mutant), 2020 0.61 [0.02; 18.27]
0.61 [0.02 ; 18.27 ] IMspire-150 (BRAF mutant), 2020 1 0% 511 NA not evaluable Chorioretinopathy TRAE (grade 3-4)detailed results IMspire-150 (BRAF mutant), 2020 0.61 [0.02; 18.27]
0.61 [0.02 ; 18.27 ] IMspire-150 (BRAF mutant), 2020 1 0% 511 NA not evaluable Decreased appetite TRAE (grade 3-4)detailed results IMspire-150 (BRAF mutant), 2020 0.30 [0.01; 6.77]
0.30 [0.01 ; 6.77 ] IMspire-150 (BRAF mutant), 2020 1 0% 511 NA not evaluable Diarrhoea TRAE (grade 3-4)detailed results IMspire-150 (BRAF mutant), 2020 0.53 [0.16; 1.76]
0.53 [0.16 ; 1.76 ] IMspire-150 (BRAF mutant), 2020 1 0% 511 NA not evaluable Dry skin TRAE (grade 3-4)detailed results IMspire-150 (BRAF mutant), 2020 4.92 [0.22; 109.67]
4.92 [0.22 ; 109.67 ] IMspire-150 (BRAF mutant), 2020 1 0% 511 NA not evaluable Erythema TRAE (grade 3-4)detailed results IMspire-150 (BRAF mutant), 2020 7.41 [0.37; 148.78]
7.41 [0.37 ; 148.78 ] IMspire-150 (BRAF mutant), 2020 1 0% 511 NA not evaluable Fatigue TRAE (grade 3-4)detailed results IMspire-150 (BRAF mutant), 2020 3.70 [0.38; 35.82]
3.70 [0.38 ; 35.82 ] IMspire-150 (BRAF mutant), 2020 1 0% 511 NA not evaluable Hyperthyroidism TRAE (grade 3-4)detailed results IMspire-150 (BRAF mutant), 2020 4.92 [0.22; 109.67]
4.92 [0.22 ; 109.67 ] IMspire-150 (BRAF mutant), 2020 1 0% 511 NA not evaluable Increased lipase level TRAE (grade 3-4)detailed results IMspire-150 (BRAF mutant), 2020 0.99 [0.64; 1.52]
0.99 [0.64 ; 1.52 ] IMspire-150 (BRAF mutant), 2020 1 0% 511 NA not evaluable Maculopapular rash TRAE (grade 3-4)detailed results IMspire-150 (BRAF mutant), 2020 1.36 [0.78; 2.37]
1.36 [0.78 ; 2.37 ] IMspire-150 (BRAF mutant), 2020 1 0% 511 NA not evaluable Myalgia TRAE (grade 3-4)detailed results IMspire-150 (BRAF mutant), 2020 2.46 [0.22; 27.26]
2.46 [0.22 ; 27.26 ] IMspire-150 (BRAF mutant), 2020 1 0% 511 NA not evaluable Nausea TRAE (grade 3-4)detailed results IMspire-150 (BRAF mutant), 2020 0.17 [0.02; 1.40]
0.17 [0.02 ; 1.40 ] IMspire-150 (BRAF mutant), 2020 1 0% 511 NA not evaluable Peripheral oedema TRAE (grade 3-4)detailed results IMspire-150 (BRAF mutant), 2020 1.22 [0.02; 61.84]
1.22 [0.02 ; 61.84 ] IMspire-150 (BRAF mutant), 2020 1 0% 511 NA not evaluable Pneumonitis TRAE (grade 3-4)detailed results IMspire-150 (BRAF mutant), 2020 4.92 [0.22; 109.67]
4.92 [0.22 ; 109.67 ] IMspire-150 (BRAF mutant), 2020 1 0% 511 NA not evaluable Pruritus TRAE (grade 3-4)detailed results IMspire-150 (BRAF mutant), 2020 2.46 [0.22; 27.26]
2.46 [0.22 ; 27.26 ] IMspire-150 (BRAF mutant), 2020 1 0% 511 NA not evaluable Pyrexia TRAE (grade 3-4)detailed results IMspire-150 (BRAF mutant), 2020 1.22 [0.24; 6.13]
1.22 [0.24 ; 6.13 ] IMspire-150 (BRAF mutant), 2020 1 0% 511 NA not evaluable Rash TRAE (grade 3-4)detailed results IMspire-150 (BRAF mutant), 2020 0.98 [0.53; 1.81]
0.98 [0.53 ; 1.81 ] IMspire-150 (BRAF mutant), 2020 1 0% 511 NA not evaluable Vomiting TRAE (grade 3-4)detailed results IMspire-150 (BRAF mutant), 2020 0.48 [0.09; 2.52]
0.48 [0.09 ; 2.52 ] IMspire-150 (BRAF mutant), 2020 1 0% 511 NA not evaluable Hypothyroidism AE (grade 3-4)detailed results IMspire-150 (BRAF mutant), 2020 1.22 [0.02; 61.84]
1.22 [0.02 ; 61.84 ] IMspire-150 (BRAF mutant), 2020 1 0% 511 NA not evaluable 0.0 20.0 1.0 relative treatment effect www.metaEvidence.org 2024-06-01 22:37 +02:00
TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers);
k: number of studies; n: total number of patients;
ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
pathologies: 127
- treatments: 204,504,850,329,558,579,549,868,502,741,556,812,813,367,851,361,602,1070,671,865,744,696,1083,1281,1282,1283,1082,866,852,417,603,1051,876,853,1018,661,673,1049,1440,854,374,1073,953,672,1080,862,855,360,719,721,720,842,642,674,1085,863,503,847,982,359,575,577,576,869,1081,981,875,505,952,1021,1079,767,1071,1074,873,561,644,1251,1044,724,874,1043,1041,1042,940,1258,746,745,856,634,861,416,864,769,980,369,743
